Regeneron Pharmaceuticals Inc.
REGN | NASDAQ
$967.49
+$39.60 (+4.27%)
Nov 2, 2026, 1:16 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 17.92 | 17.42 | 23.71 | 17.81 | 8.27 | 14.80 |
PEG Ratio | 3.38 | 1.68 | -2.78 | -0.38 | 0.06 | 0.22 |
PS Ratio | 5.63 | 5.41 | 7.14 | 6.35 | 4.15 | 6.12 |
PB Ratio | 2.58 | 2.62 | 3.61 | 3.41 | 3.56 | 4.71 |
P/FCF Ratio | 19.79 | 20.97 | 25.55 | 17.46 | 10.22 | 25.95 |
P/OCF Ratio | 16.22 | 17.39 | 20.40 | 15.41 | 9.43 | 19.86 |
OCF/S Ratio | 34.71 | 31.13 | 35.02 | 41.20 | 44.06 | 30.81 |
Debt / Equity Ratio | 0.09 | 0.09 | 0.10 | 0.12 | 0.14 | 0.24 |
Quick Ratio | 3.39 | 3.95 | 4.94 | 4.29 | 3.07 | 2.91 |
Current Ratio | 4.13 | 4.73 | 5.69 | 5.06 | 3.56 | 3.63 |
Asset Turnover | 0.35 | 0.38 | 0.40 | 0.42 | 0.63 | 0.50 |
Interest Coverage | 81.69 | 72.30 | 59.57 | 90.67 | 156.14 | 62.86 |
Return on Equity | 14.41% | 15.03% | 15.22% | 19.14% | 43.03% | 31.86% |
Return on Assets | 11.11% | 11.69% | 11.95% | 14.85% | 31.75% | 20.47% |
Return on Invested Capital | 8.51% | 10.89% | 13.81% | 18.44% | 34.86% | 22.80% |
Dividend Yield | 0.46% | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | 8.22% | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | 12% | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 85.35% | 86.13% | 82.89% | 85.99% | 83.05% | 84.04% |
Net Profit Margin | 31.41% | 31.07% | 30.14% | 35.64% | 50.25% | 41.35% |
Pretax Profit Margin | 36.47% | 33.66% | 32.01% | 39.91% | 58.03% | 44.84% |
Operating Profit Margin | 24.95% | 28.10% | 33.15% | 44.24% | 55.67% | 42.09% |
FCF Margin | 28.45% | 25.80% | 27.96% | 36.35% | 40.63% | 23.58% |
EBITDA Margin | 40.56% | 37.45% | 35.78% | 43.21% | 60.16% | 48.29% |
Add to Watchlist
Select watchlists to add or remove REGN